High Resolution Ultrasound in Pancreatic Ductal Adenocarcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03820661 |
Recruitment Status :
Recruiting
First Posted : January 29, 2019
Last Update Posted : September 2, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pancreatic Ductal Adenocarcinoma | Device: Ultrasound | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Advancing The Local Staging Of Pancreatic Ductal Adenocarcinoma Through High-Resolution Ultrasound: A Pilot Study |
Actual Study Start Date : | February 1, 2019 |
Estimated Primary Completion Date : | February 2021 |
Estimated Study Completion Date : | February 2021 |
Arm | Intervention/treatment |
---|---|
High Resolution Ultasound
Diagnostic high resolution ultrasound pre-operatively and intraoperatively
|
Device: Ultrasound
High resolution ultrasound pre-operatively and intra-operatively |
- High-resolution U/S will be used to measure vascular invasion and regional lymph node metastases in PDAC [ Time Frame: within 2 weeks of surgery ]The U/S results will be compared to pre-operative CT scan to help determine the diagnostic effectiveness of High Resolution US

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Males and females > 18 y
- PDAC diagnosed by typical imaging findings or pathology
- Scheduled for surgical resection
- Contrast enhanced CT scan performed locally at UHN
Exclusion Criteria:
1) Inability or unwillingness to provide informed consent

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03820661
Contact: Stephanie Ramotar | 416-946-4501 ext 2657 | Stephanie.Ramotar@uhn.ca | |
Contact: Dorian Anglin Facey | 416 340 4800 ext 5095 | dorian.facey@uhn.ca |
Canada, Ontario | |
University Health Network | Recruiting |
Toronto, Ontario, Canada, M5G 2C4 | |
Contact: Dorian Facey 4377797757 | |
Contact: Stephanie Ramotar | |
Principal Investigator: Korosh Khalili |
Principal Investigator: | Korosh Khalili, MD | UHN |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT03820661 |
Other Study ID Numbers: |
18-5982 |
First Posted: | January 29, 2019 Key Record Dates |
Last Update Posted: | September 2, 2020 |
Last Verified: | September 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |